Success Metrics

Active Trials
5(83%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Other(1)

Detailed Status

Recruiting3
Active, not recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

active_not_recruiting233%
recruiting350%
unknown117%

Recent Activity

5 active trials
Showing 5 of 6
recruitingphase_1

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

NCT05342584
recruitingphase_1

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03850574
active_not_recruitingphase_2

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

NCT04082897
recruitingphase_2

VA vs DA for Newly Diagnosed Hig-risk AML

NCT05939180
active_not_recruitingphase_1

Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

NCT04330820
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05342584Phase 1

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

Recruiting
NCT03850574Phase 1

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
NCT04082897Phase 2

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active Not Recruiting
NCT05939180Phase 2

VA vs DA for Newly Diagnosed Hig-risk AML

Recruiting
NCT04330820Phase 1

Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

Active Not Recruiting
NCT06087419Phase 1

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6